Philips’ DEFINE GPS Trial Will Assess Outcomes of PCI Guided by an Integrated Platform of iFR and Angiogram
February 11, 2020—Royal Philips announced a new randomized controlled trial to assess patient outcomes after receiving percutaneous coronary intervention (PCI) guided by Philips’ coregistration platform (which combines data of instant wave-free ratio (iFR) measurement and angiography) compared with the standard of care treatment guided by angiography alone.
Study Demonstrates Relationship Between Hospital SAVR Volume and TAVR Outcomes
February 10, 2020—Sameer A. Hirji, MD, et al conducted a study that examined whether hospital surgical aortic valve replacement (SAVR) volume was associated with corresponding transcatheter aortic valve replacement (TAVR) outcomes. The investigators published the findings from the study in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2020;13:335–343).
JenaValve Technology Closes $50 Million Financing Equity Round
February 5, 2020—JenaValve Technology, Inc. announced that it has raised $50 million in equity financing to support an ongoing clinical program for the company’s JenaValve pericardial transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease.
CardioFocus Makes PMA Supplement Submission to FDA for the HeartLight X3 Endoscopic Ablation System
February 4, 2020—CardioFocus, Inc. announced that it has submitted a premarket approval (PMA) supplement to the FDA for the company’s HeartLight X3 endoscopic ablation system to treat atrial fibrillation (AF).
Medtronic Begins SPYRAL DYSTAL Pilot Study of Renal Denervation in Hypertensive Patients
February 4, 2020—Medtronic announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity Spyral renal denervation (RDN) system using a targeted procedural approach with a reduced number of radiofrequency (RF) ablations.